PDS Biotechnology Corp
PDS Biotechnology Corporation (Nasdaq: PDSB) is a clinical-stage immunotherapy company developing treatments for cancer and preventive vaccines for infectious diseases. Its oncology programs use Versamune®, a T cell-activating platform combined with disease-related antigens, alone or with PDS01ADC, an investigational… From the company’s description.
In fiscal 2025, PDS Biotechnology Corp reported a net loss of $34.50M. Operations used $27.75M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PDS Biotechnology Corp does
In the company’s own words
PDS Biotechnology Corporation (Nasdaq: PDSB) is a clinical-stage immunotherapy company developing treatments for cancer and preventive vaccines for infectious diseases. Its oncology programs use Versamune®, a T cell-activating platform combined with disease-related antigens, alone or with PDS01ADC, an investigational tumor-targeting interleukin-12 antibody drug conjugate; the Infectimune® platform is being developed for infectious disease vaccines. The pipeline includes PDS0101, a Versamune-based candidate targeting HPV-related cancers, and PDS0103 for cancers associated with MUC1. The company is evaluating candidates in clinical trials, including combinations with checkpoint inhibitors and standard-of-care treatments. Its products are intended for patients with cancer or at risk of infectious disease, with clinical programs conducted by the company and research collaborators. The filing describes one operating business focused on research and development and does not report revenue segments. As of fiscal 2025, PDS Biotechnology is clinical-stage, with no commercial product sales described. Its website is www.pdsbiotech.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PRINCETON, NJ
- Fiscal year end
- December
- CIK
- 1472091
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PDS Biotechnology Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PDS Biotechnology Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PDS Biotechnology Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PDS Biotechnology Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PDS Biotechnology Corp's last four quarterly filings that the numbers alone won't show?”